# Drug Scheduling: Resources

This section provides a curated list of key research, government reports, legal sources, and advocacy organizations on drug scheduling, classification reform, and the science of controlled substances.

---

## Academic Research

### Peer-Reviewed Studies

- Nutt, David J., Leslie A. King, and Lawrence D. Phillips. "Drug Harms in the UK: A Multicriteria Decision Analysis." *The Lancet* 376.9752 (2010): 1558-1565. <https://doi.org/10.1016/S0140-6736(10)61462-6> - Landmark study ranking 20 drugs by 16 harm criteria; found scheduling bears little relation to evidence-based harm.
- Nutt, David, Leslie A. King, William Saulsbury, and Colin Blakemore. "Development of a Rational Scale to Assess the Harm of Drugs of Potential Misuse." *The Lancet* 369.9566 (2007): 1047-1053. <https://doi.org/10.1016/S0140-6736(07)60464-4>
- Vergara, Daniela, et al. "Compromised External Validity: Federally Produced Cannabis Does Not Reflect Legal Markets." *Scientific Reports* 7 (2017): 46528. <https://doi.org/10.1038/srep46528> - Documented potency gap between NIDA research cannabis and market products.
- Stith, Sarah S., et al. "Comparison of Research-Grade vs Commercially Available Cannabis Products." *JAMA Network Open* 5.5 (2022): e2212903.
- Carhart-Harris, Robin L., et al. "Trial of Psilocybin versus Escitalopram for Depression." *New England Journal of Medicine* 384.15 (2021): 1402-1411. <https://doi.org/10.1056/NEJMoa2032994>
- Mitchell, Jennifer M., et al. "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study." *Nature Medicine* 27 (2021): 1025-1033. <https://doi.org/10.1038/s41591-021-01336-3>
- Volkow, Nora D., et al. "Effects of Cannabis Legalization on Cannabis Use Disorders and Cannabis Use Among Adults and Adolescents." *JAMA Psychiatry* 79.1 (2022): 26-32.

### Working Papers and White Papers

- Hudak, John. "The Farm Bill, Hemp Legalization, and the Status of CBD: An Explainer." Brookings Institution. 2018. <https://www.brookings.edu/articles/the-farm-bill-hemp-legalization-and-the-status-of-cbd-an-explainer/>
- Hudak, John. "The DEA's Scheduling of Marijuana: A History of Politics Trumping Science." Brookings Institution. 2022. <https://www.brookings.edu/articles/the-deas-scheduling-of-marijuana/>
- Pardo, Bryce, et al. "The Future of Fentanyl and Other Synthetic Opioids." RAND Corporation. 2019. <https://www.rand.org/pubs/research_reports/RR3117.html>

---

## Government Reports and Data

### Federal Agencies

- Drug Enforcement Administration. "Schedules of Controlled Substances." 21 C.F.R. Part 1308. Updated annually. <https://www.deadiversion.usdoj.gov/schedules/>
- Drug Enforcement Administration. "National Drug Threat Assessment 2024." 2024. <https://www.dea.gov/documents/2024/05/drug-threat-assessment>
- Department of Health and Human Services. "Recommendation to Reschedule Marijuana." Letter from HHS Assistant Secretary for Health to DEA Administrator. August 29, 2023.
- Food and Drug Administration. "FDA and Cannabis: Research and Drug Approval Process." Updated 2024. <https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis>
- Substance Abuse and Mental Health Services Administration. "National Survey on Drug Use and Health (NSDUH): 2023 Annual Report." 2024. <https://www.samhsa.gov/data/report/nsduh-annual-report>
- Centers for Disease Control and Prevention. "Wide-ranging Online Data for Epidemiologic Research (WONDER)." Multiple Cause of Death database. <https://wonder.cdc.gov/> - Drug overdose mortality data.
- Office of National Drug Control Policy. "National Drug Control Budget: FY2025 Funding Highlights." 2024. <https://www.whitehouse.gov/ondcp/>

### Congressional Reports

- Congressional Research Service. "The Controlled Substances Act (CSA): A Legal Overview for the 118th Congress." Report R45948. 2023. <https://crsreports.congress.gov/product/pdf/R/R45948>
- Congressional Research Service. "Marijuana Rescheduling: Legal and Policy Issues." Report R47931. 2024. <https://crsreports.congress.gov/product/pdf/R/R47931>
- Congressional Research Service. "The Federal Analogue Act: Legal Issues." Report LSB10702. 2022.
- Government Accountability Office. "Drug Control: DEA's Scheduling Process for Controlled Substances." GAO-22-105250. 2022.
- Government Accountability Office. "Marijuana Research: HHS and DEA Should Improve the Federal Process for Approving Research." GAO-22-104387. 2021.

### Agency Data Portals

- DEA Diversion Control Division. Controlled Substance Registration Data. <https://www.deadiversion.usdoj.gov/> - Researcher registration counts, manufacturing quotas, scheduling actions.
- FDA Clinical Trials Database (ClinicalTrials.gov). <https://clinicaltrials.gov/> - Active and completed clinical trials for controlled substances.
- SAMHSA National Survey on Drug Use and Health Data Portal. <https://pdas.samhsa.gov/> - Annual data on substance use, treatment, and access.

---

## Books

- Hari, Johann. *Chasing the Scream: The First and Last Days of the War on Drugs*. Bloomsbury, 2015. - Narrative history of the War on Drugs and its alternatives.
- Hart, Carl L. *Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear*. Penguin Press, 2021. - Neuroscientist's argument for rational drug policy based on scientific evidence.
- Alexander, Michelle. *The New Jim Crow: Mass Incarceration in the Age of Colorblindness*. The New Press, 2010. - Analysis of racial dimensions of drug enforcement and mass incarceration.
- Pollan, Michael. *How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence*. Penguin Press, 2018. - Overview of psychedelic research renaissance and Schedule I barriers.
- Musto, David F. *The American Disease: Origins of Narcotic Control*. 3rd ed. Oxford University Press, 1999. - Definitive history of American drug regulation from the 19th century through the CSA.
- Siff, Stephen. *Acid Hype: American News Media and the Psychedelic Experience*. University of Illinois Press, 2015. - Media's role in shaping public perception of psychedelics and influencing scheduling decisions.
- Baum, Dan. *Smoke and Mirrors: The War on Drugs and the Politics of Failure*. Back Bay Books, 1997. - Investigative account of the political origins of the War on Drugs.

---

## Think Tank Analysis

### Research Organizations

- Brookings Institution. "Marijuana Policy and Federalism." Ongoing research series. <https://www.brookings.edu/topic/marijuana-policy/> - Analysis of federal-state cannabis conflicts and scheduling reform.
- Cato Institute. "Drug Policy and Decriminalization." <https://www.cato.org/research/drug-policy> - Libertarian analysis of drug prohibition and scheduling.
- RAND Corporation. Drug Policy Research Center. <https://www.rand.org/well-being/justice-policy/centers/dprc.html> - Rigorous quantitative analysis of drug policy effectiveness, including cost-effectiveness of treatment vs. enforcement.
- National Academies of Sciences, Engineering, and Medicine. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. 2017. <https://doi.org/10.17226/24625> - Comprehensive evidence review; identified Schedule I research barriers.

### Policy Briefs

- Drug Policy Alliance. "Fact Sheet: Drug Scheduling." 2023. <https://drugpolicy.org/resources/>
- Marijuana Policy Project. "Federal Marijuana Policy." 2024. <https://www.mpp.org/issues/federal/>
- Smart Approaches to Marijuana. "Why Rescheduling Is Not the Answer." 2024. <https://learnaboutsam.org/> - Opposing perspective on cannabis rescheduling.

---

## Organizations and Advocacy Groups

| Organization | Focus | Type | Website |
|--------------|-------|------|---------|
| Drug Policy Alliance (DPA) | Comprehensive drug policy reform, decriminalization, harm reduction | Advocacy | <https://drugpolicy.org/> |
| NORML | Cannabis legalization and scheduling reform | Advocacy | <https://norml.org/> |
| Multidisciplinary Association for Psychedelic Studies (MAPS) | Psychedelic research, MDMA/psilocybin rescheduling | Research/Advocacy | <https://maps.org/> |
| Americans for Safe Access (ASA) | Medical cannabis patient access, scheduling reform | Advocacy/Legal | <https://www.safeaccessnow.org/> |
| National Cannabis Industry Association (NCIA) | Cannabis industry policy, federal reform | Trade Association | <https://thecannabisindustry.org/> |
| Marijuana Policy Project (MPP) | State and federal cannabis legalization | Advocacy | <https://www.mpp.org/> |
| Smart Approaches to Marijuana (SAM) | Oppose cannabis commercialization; skeptical of rescheduling | Advocacy (opposing) | <https://learnaboutsam.org/> |
| National Organization of State and Local Drug Enforcement (NOSLDE) | Law enforcement perspective on drug scheduling | Professional Association | Various state chapters |
| Usona Institute | Psilocybin research for depression | Research | <https://www.usonainstitute.org/> |

---

## Data Sources

| Dataset | Provider | Update Frequency | URL | Description |
|---------|----------|------------------|-----|-------------|
| Schedules of Controlled Substances | DEA | Ongoing (as actions occur) | <https://www.deadiversion.usdoj.gov/schedules/> | Complete list of all federally scheduled substances |
| National Survey on Drug Use and Health | SAMHSA | Annual | <https://www.samhsa.gov/data/data-we-collect/nsduh> | Drug use prevalence, treatment access, substance use disorders |
| CDC WONDER Multiple Cause of Death | CDC | Annual | <https://wonder.cdc.gov/> | Drug overdose mortality data by substance, geography, demographics |
| ClinicalTrials.gov | NIH/FDA | Ongoing | <https://clinicaltrials.gov/> | Registry of active and completed clinical trials for controlled substances |
| FBI Uniform Crime Reporting | FBI | Annual | <https://crime-data-explorer.fr.cloud.gov/> | Drug arrest data by offense type, geography, demographics |
| State Cannabis Legalization Tracker | NCSL | Ongoing | <https://www.ncsl.org/health/state-medical-cannabis-laws> | Status of state cannabis laws |

---

## News and Journalism

### Investigative Reports

- Baum, Dan. "Legalize It All." *Harper's Magazine*. April 2016. <https://harpers.org/archive/2016/04/legalize-it-all/> - Contains the Ehrlichman admission about the racial motivations of the War on Drugs.
- Ingraham, Christopher. "DEA: Marijuana Is as Dangerous as Heroin, But the Feds Are OK with Meth." *Washington Post*. August 11, 2016. - Analysis of scheduling inconsistencies.
- Tvert, Mason and Steve Fox. "Marijuana vs. Alcohol: Which Is Really Worse for Your Health?" Numerous outlets, ongoing. - Comparative harm analysis.

### Ongoing Coverage

- *Marijuana Moment*. Daily cannabis policy coverage including federal scheduling developments. <https://www.marijuanamoment.net/>
- *STAT News*. Psychedelic therapy and FDA regulatory coverage. <https://www.statnews.com/>
- *Filter Magazine*. Drug policy, harm reduction, and scheduling reform. <https://filtermag.org/>

---

## International Sources

- United Nations Office on Drugs and Crime. "World Drug Report 2024." 2024. <https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2024.html>
- International Narcotics Control Board. "Annual Report 2023." <https://www.incb.org/incb/en/publications/annual-reports/annual-report.html>
- European Monitoring Centre for Drugs and Drug Addiction. "European Drug Report 2024." <https://www.emcdda.europa.eu/publications/european-drug-report_en>
- Health Canada. "Cannabis in Canada: 2023 National Cannabis Survey." <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis.html>
- Australian Government Therapeutic Goods Administration. "Access to Medicinal Cannabis and Other Therapeutic Goods." <https://www.tga.gov.au/products/medicines/medicinal-cannabis>

---

## Legal Resources

### Case Law

- *Gonzales v. Raich*, 545 U.S. 1 (2005). - Upheld federal authority to prohibit cannabis even in states with medical programs under Commerce Clause.
- *Americans for Safe Access v. DEA*, 706 F.3d 438 (D.C. Cir. 2013). - Upheld DEA denial of cannabis rescheduling petition; court deferred to DEA interpretation of "accepted medical use."
- *Sisley v. DEA*, No. 20-71433 (9th Cir. 2020). - Required DEA to process cannabis research cultivation applications in timely manner.
- *Washington v. Barr*, 925 F.3d 109 (2d Cir. 2019). - Dismissed challenge to cannabis Schedule I status for failure to exhaust administrative remedies.
- *United States v. McFadden*, 823 F.3d 217 (4th Cir. 2016). - Addressed knowledge requirements under the Federal Analogue Act.
- *Webb v. United States*, 249 U.S. 96 (1919). - Early case interpreting Harrison Act as prohibiting physician prescribing of opiates to addicted patients.

### Statutory References

- 21 U.S.C. Sections 801-904 (Controlled Substances Act) - Federal scheduling framework.
- 21 U.S.C. Section 811 - Scheduling authority and procedures.
- 21 U.S.C. Section 812 - Schedule definitions and initial substance placements.
- 21 U.S.C. Section 813 - Federal Analogue Act.
- 21 U.S.C. Section 823 - Registration requirements for researchers and practitioners.
- 26 U.S.C. Section 280E - Prohibition on business deductions for Schedule I/II substance traffickers.
- 21 C.F.R. Part 1301 - DEA registration requirements.
- 21 C.F.R. Part 1308 - Schedules of controlled substances.

---

## Document Navigation

- Up: [Drug Policy Overview](../01-overview.md)
- Previous: [Roadmap](08-roadmap.md)
- Next: [Actions](10-actions.md)
